Additionally, the development of specific WBP1 inhibitors and their evaluation in combination with chemotherapeutic agents in preclinical and clinical settings could lead to novel therapeutic strategies for overcoming chemoresistance in CRC patients. The gene discussed is WBP1; the disease is colorectal carcinoma.